Takeda Pharmaceutical Company (4502) Q1 2025 earnings summary

Executive summary

• Q1 FY2024 revenue grew 2.1% at constant exchange rates (CER) to JPY 1,208.0 billion, with growth and launch products up 17.8% at CER, now representing 46% of total revenue; reported revenue rose 14.1% year-over-year, driven by favorable FX and strong performance in GI, Rare Diseases, PDT, Oncology, and Vaccines, partially offset by Neuroscience declines due to generic competition.

• Core operating profit margin reached 31.6% in Q1, aided by R&D phasing, lower OPEX, and slower-than-expected Vyvanse generic erosion; reported operating profit margin was 13.8% due to restructuring and impairment costs.

• Net profit attributable to owners increased 6.5% year-over-year to JPY 95.2 billion (reported), while core EPS rose 17.5% to JPY 176.

• Key product launches and geographic expansions included Entyvio Pen in the U.S., Livtencity in Japan, Fruzaqla in Europe, and Qdenga in new markets.

• Pipeline progress included option agreements for Olverembatinib (CML) and ACI-24.060 (Alzheimer's), and organic advances with multiple phase III programs; Soticlestat phase III trials failed to meet primary endpoints but showed potential in secondary endpoints.

Financial highlights

• Q1 revenue: JPY 1,208.0 billion (+14.1% reported, +2.1% CER year-over-year), driven by growth and launch products and favorable FX.

• Core operating profit: JPY 382.3 billion (+17.1% reported, +4.5% CER); reported operating profit: JPY 166.3 billion (-1.3% year-over-year) due to restructuring and impairment.

• Core EPS: JPY 176; reported EPS: JPY 61.

• Operating cash flow: JPY 170.3 billion (+84.3% year-over-year); adjusted free cash flow: JPY 23.7 billion (vs. -207.5 billion prior year).

• Gross margin: 68.0% in Q1, down 1.7pp year-over-year, expected to decline to 65.5% for the full year.

Outlook and guidance

• FY2024 revenue forecast: JPY 4,350.0 billion (+2.0% year-over-year); core operating profit: JPY 1,000.0 billion (-5.2%); reported operating profit: JPY 225.0 billion (+5.1%).

• EPS forecast: 37 yen (reported), 431 yen (core); adjusted free cash flow: JPY 350.0–450.0 billion.

• Vyvanse global revenue expected to decline 49% at CER; generic erosion impact to accelerate.

• R&D investment weighted to H2 as multiple phase III programs begin; restructuring expenses forecast at JPY 140 billion.

• Management guidance at CER: core revenue flat to slightly declining, core OP down ~10%, core EPS down mid-teens percent.